Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Feb 1, 2025 | (Q4)Feb 1, 2025 | (Q3)Nov 2, 2024 | (Q2)Aug 3, 2024 | (Q1)May 4, 2024 | (FY)Feb 3, 2024 | (Q4)Feb 3, 2024 | (Q3)Oct 28, 2023 | (Q2)Jul 29, 2023 | (Q1)Apr 29, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 22.67%1.68B | -5.96%514M | 6.62%536.3M | 172.36%306.4M | 55.71%324.5M | 6.34%1.37B | 55.50%546.6M | 22.38%503M | -66.06%112.5M | 6.98%208.4M |
Net income from continuing operations | 5.19%-885M | 150.98%200.2M | -311.63%-676.3M | 6.84%-193.3M | -27.65%-215.6M | -470.89%-933.4M | -2,450.00%-392.7M | -1,335.34%-164.3M | -4,925.58%-207.5M | -1.93%-168.9M |
Depreciation and amortization | -2.92%1.36B | -9.50%325.9M | -0.12%341.5M | 1.35%352M | -3.13%337.5M | 0.39%1.4B | 2.56%360.1M | -0.70%341.9M | -0.40%347.3M | 0.06%348.4M |
Deferred tax | -174.20%-111.9M | -101.31%-5.7M | 15.96%-47.9M | 58.79%-36.1M | 84.04%-22.2M | 199.21%150.8M | 13,678.13%434.5M | 54.33%-57M | -753.73%-87.6M | -184.30%-139.1M |
Other non cash items | 20.04%65.9M | 58.67%23.8M | -50.55%9M | 26.97%11.3M | 70.31%21.8M | -45.86%54.9M | -31.19%15M | -56.35%18.2M | -60.96%8.9M | -15.23%12.8M |
Change In working capital | 123.36%129.1M | -593.92%-182.5M | 12.15%229.8M | 113.04%16M | 3,363.16%65.8M | 108.90%57.8M | 80.40%-26.3M | 1,726.19%204.9M | 39.62%-122.7M | 100.63%1.9M |
-Change in receivables | 32.01%93.2M | -132.80%-30.5M | 1,230.91%62.2M | 14.41%-178.2M | 25.30%239.7M | 149.47%70.6M | -53.22%93M | 94.60%-5.5M | -107.78%-208.2M | 237.13%191.3M |
-Change in inventory | -213.92%-230M | -315.48%-169.8M | -253.26%-108.2M | -18.58%9.2M | -5.83%38.8M | 152.32%201.9M | 164.33%78.8M | 225.40%70.6M | 113.90%11.3M | 132.75%41.2M |
-Change in prepaid assets | 103.65%3.4M | -60.74%-172.8M | -184.73%-45.5M | 387.92%135.9M | 986.08%85.8M | 80.62%-93.1M | -9.69%-107.5M | 127.19%53.7M | -12.38%-47.2M | 105.53%7.9M |
-Change in payables and accrued expense | 315.87%262.5M | 310.38%190.6M | 273.17%321.3M | -59.56%49.1M | -25.16%-298.5M | -133.85%-121.6M | 19.47%-90.6M | -74.90%86.1M | 498.03%121.4M | -320.02%-238.5M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 22.67%1.68B | -5.96%514M | 6.62%536.3M | 172.36%306.4M | 55.71%324.5M | 6.34%1.37B | 55.50%546.6M | 22.38%503M | -66.06%112.5M | 6.98%208.4M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 14.21%-300.7M | 7.74%-70.3M | -38.28%-75.5M | 54.70%-53M | 0.78%-101.9M | -6.73%-350.5M | -18.69%-76.2M | -5.20%-54.6M | 9.93%-117M | -24.64%-102.7M |
Net PPE purchase and sale | 15.37%-284.6M | 1.55%-69.9M | -37.87%-75M | 56.62%-48.2M | 8.32%-91.5M | -63.09%-336.3M | -31.48%-71M | -27.40%-54.4M | -53.03%-111.1M | -170.46%-99.8M |
Net intangibles purchase and sale | 49.64%-7M | 92.45%-800K | -66.67%-500K | -2,500.00%-5.2M | 82.14%-500K | -25.23%-13.9M | -430.00%-10.6M | 93.88%-300K | 92.31%-200K | -75.00%-2.8M |
Net business purchase and sale | ---10.4M | --0 | --0 | ---- | ---- | --0 | 159.14%5.5M | --0 | ---- | ---- |
Net other investing changes | 533.33%1.3M | 500.00%400K | --0 | 5,500.00%10.8M | -9,800.00%-9.9M | -125.00%-300K | -109.09%-100K | --100K | ---200K | -200.00%-100K |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 14.21%-300.7M | 7.74%-70.3M | -38.28%-75.5M | 54.70%-53M | 0.78%-101.9M | -6.73%-350.5M | -18.69%-76.2M | -5.20%-54.6M | 9.93%-117M | -24.64%-102.7M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -41.09%-1.38B | -48.25%-363.5M | -174.56%-401.4M | 51.30%-292.4M | -2,907.76%-325.7M | -47.87%-980.2M | -145.94%-245.2M | 42.17%-146.2M | -1,112.93%-600.4M | 104.45%11.6M |
Net issuance payments of debt | 66.56%-109.4M | -49.77%-32.8M | -185.42%-32.8M | 95.80%-21.9M | -112.30%-21.9M | -398.78%-327.2M | -0.46%-21.9M | 141.78%38.4M | -984.41%-521.8M | 1,733.94%178.1M |
Net common stock issuance | -383.33%-725M | -100.00%-200M | -300.00%-200M | ---175M | ---150M | -30.43%-150M | ---100M | 0.00%-50M | --0 | --0 |
Cash dividends paid | -0.34%-207.5M | 0.00%-51.9M | -0.19%-51.9M | -0.39%-51.9M | -0.78%-51.8M | -1.17%-206.8M | -1.17%-51.9M | -1.37%-51.8M | -1.17%-51.7M | -0.98%-51.4M |
Proceeds from stock option exercised by employees | -11.69%87.6M | -7.61%35.2M | 14.29%800K | -6.81%49.3M | -69.33%2.3M | 8.65%99.2M | -1.80%38.1M | -36.36%700K | 8.18%52.9M | 200.00%7.5M |
Net other financing activities | -8.42%-428.7M | -4.11%-114M | -40.72%-117.5M | -16.42%-92.9M | 14.93%-104.3M | -7.10%-395.4M | -67.43%-109.5M | -37.11%-83.5M | -41.74%-79.8M | 34.30%-122.6M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -41.09%-1.38B | -48.25%-363.5M | -174.56%-401.4M | 51.30%-292.4M | -2,907.76%-325.7M | -47.87%-980.2M | -145.94%-245.2M | 42.17%-146.2M | -1,112.93%-600.4M | 104.45%11.6M |
Net cash flow | ||||||||||
Beginning cash position | 4.37%950.8M | 19.64%868.1M | 91.00%808.7M | -17.56%847.7M | 4.37%950.8M | 48.49%911M | 0.30%725.6M | -31.39%423.4M | 121.14%1.03B | 48.49%911M |
Current changes in cash | -106.28%-2.5M | -64.39%80.2M | -80.34%59.4M | 93.55%-39M | -187.89%-103.1M | -86.62%39.8M | 20.04%225.2M | 184.29%302.2M | -497.70%-604.9M | 178.99%117.3M |
End cash Position | -0.26%948.3M | -0.26%948.3M | 19.64%868.1M | 91.00%808.7M | -17.56%847.7M | 4.37%950.8M | 4.37%950.8M | 0.30%725.6M | -31.39%423.4M | 121.14%1.03B |
Free cash flow | 36.20%1.39B | -4.67%443.3M | 2.79%460.8M | 20,983.33%253M | 119.75%232.5M | -4.78%1.02B | 57.36%465M | 23.36%448.3M | -99.53%1.2M | -32.31%105.8M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |